Braintree Laboratories, Inc. v. Nephro-Tech, Inc.

99 F. Supp. 2d 1300, 2000 U.S. Dist. LEXIS 8033, 2000 WL 744373
District Court, D. Kansas·Decided May 16, 2000·No. 96-2459-JWL·Published·Cited by 4 cases

Opinion

MEMORANDUM AND ORDER

LUNGSTRUM, District Judge.

Plaintiff Braintree Laboratories, Inc., the assignee of United States Patent No. 4,870,105, (hereafter ’105 patent) brought this patent infringement action against defendants Nephro-Tech, Inc. and G.P. Georges III, alleging that defendants’ mar *1303 keting and distribution of their calcium acetate product infringes the ’105 patent. A jury trial in this matter was held before this court between September 28, 1999 and October 7, 1999. On October 7, 1999, the jury returned a verdict in favor of plaintiff, finding the ’105 patent valid and infringed, and awarding damages in the amount of $800,000. After considering the parties’ respective post-trial motions, the court denied defendants’ motion for judgment as a matter of law, and granted in part plaintiffs motion to alter or amend the judgment. See Braintree Labs., Inc. v. Nephro-Tech, Inc., 81 F.Supp.2d 1122 (D.Kan.2000). Presently before the court is plaintiffs motion for an order to show cause why defendants should not be held in contempt for failure to comply with the injunction provision of the court’s judgment (doc. 168). For the reasons set forth below, plaintiffs motion is denied.

I. Standard

The primary purpose of a civil 1 contempt sanction is “to enforce compliance with an order of the court or to compensate for losses or damages sustained by reason of noncomplianee.” Law v. National Collegiate Athletic Ass’n, 134 F.3d 1438, 1442 (10th Cir.1998) (quoting McComb v. Jacksonville Paper Co., 336 U.S. 187, 191, 69 S.Ct. 497, 93 L.Ed. 599 (1949)). A party seeking a contempt order bears the burden to establish, by clear and convincing evidence, that “a valid court order existed, that the defendant had knowledge of the order, and that the defendant disobeyed the order.” Reliance Ins. Co. v. Mast Const. Co., 159 F.3d 1311, 1315 (10th Cir.1998).

To the extent that the order alleged to have been violated is ambiguous or otherwise unclear, “[a]ny ambiguities or omissions in the order will be construed in favor of [the person charged with violating the order].” Id. “A .defendant may be absolved from a finding of civil contempt if the defendant is able to show that it complied with a reasonable interpretation of the stipulation and order and if the defendant’s action appears to be based on a good faith and reasonable interpretation of the order.” Spectra Sonics Aviation, Inc. v. Ogden City, 931 F.2d 63 (table), 1991 WL 59369, at 2 (10th Cir.1991) (citing McComb v. Jacksonville Paper Co., 336 U.S. 187, 69 S.Ct. 497, 93 L.Ed. 599 (1949)); Entech Sys., Inc. v. Bhaskar, 72 F.Supp.2d 1272, 1276 (D.Kan.1999). Moreover, “if the defendant takes all reasonable steps and substantially complies with the court order,” a finding of civil contempt may be avoided. Spectra Sonics, 1991 WL 59369, at 2 (citing General Signal Corp. v. Donallco, Inc., 787 F.2d 1376, 1379 (9th Cir.1986)); Bhaskar, 72 F.Supp.2d at 1276.

Where the movant establishes a prima facie case of civil contempt, the district court nevertheless retains broad discretion in determining whether to exercise its authority to hold a party in contempt. Id.; see also United Intern. Holdings, Inc. v. The Wharf (Holdings) Ltd., 210 F.3d 1207, 1236-37 (10th Cir.2000) (citing O’Connor v. Midwest Pipe Fabrications, Inc., 972 F.2d 1204, 1209 (10th Cir.1992) (“A district court has broad discretion in using its contempt power to require adherence to court orders”)). Finally, the court notes that “[c]ivil contempt is an appropriate remedy for the enforcement of a judicial decree, but it is a severe one which should be used only when necessary to sustain the authority of the court.” NLRB v. Shurtenda Steaks, Inc., 424 F.2d 192, *1304 194 (10th Cir.1970); T.Y. v. Board of County Comm’rs of County of Shawnee, 912 F.Supp. 1424, 1427 (D.Kan.1996).

II. Discussion

Although defendants continued to sell their Calphron product during trial, defendants explain that, in an effort to avoid any further litigation with regard to the sale of Calphron, they have elected to stop selling the product altogether. Thus, according to defendants, the last sale of Calphron occurred on January 8, 2000, four days before this court denied defendants’ post-trial motion and granted plaintiffs request for injunctive relief. Additionally, although not required to do so by any order issued by this court, defendants state that they have advised the National Databank, which, according to the defendants, is “an organization that provides product information to wholesalers, pharmacies and state Medicaid payors,” that Calphron is no longer available for sale. Def.Mem. in Opp. at 1.

A. State Agencies

1. Any State Agency Which Could Possibly Reimburse for Calphron

Plaintiff contends that the injunction entered by the court on January 7, 2000 requires defendants to alert “any state agency which could pay reimbursement for Calphron, not just agencies which have paid reimbursement previously.” Def. Repl. at 3. Defendants, on the other hand, maintain that the injunction directs defendants to send notices only to state agencies from which it had in the past received, or was currently receiving, Medicaid reimbursement for their Calphron product. The disputed language of the injunction reads as follows:

IT IS FURTHER ORDERED THAT the defendants, Nephro-Tech, Inc., and G.P. Georges III, send written notice of this injunction, by a copy thereof, to all of their present and past customers, distributors, wholesalers, warehousers, dialysis clinics, doctors, and other health care providers in the nephrology community, and all agencies or entities making payment for reimbursement for any purchase, of the product Calphron.

Braintree, 81 F.Supp.2d. at 1141 (emphasis added).

Free access — add to your briefcase to read the full text and ask questions with AI

Braintree Laboratories, Inc. v. Nephro-Tech, Inc., 99 F. Supp. 2d 1300, 2000 U.S. Dist. LEXIS 8033, 2000 WL 744373 (D. Kan. 2000).

99 F. Supp. 2d 1300 (Braintree Laboratories, Inc. v. Nephro-Tech, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Borrego
D. New Mexico, 2023
Williams v. Commandant
D. Kansas, 2021
Woodson v. Green
191 F. Supp. 2d 1231 (D. Kansas, 2002)